OM1’s state-of-the-art PhenOM® AI model powers digital phenotyping and medical event predictions. It accelerates patient finding for undiagnosed conditions, predicts disease progression and adverse events, estimates treatment response and forecasts outcomes for individuals and populations.




Healthcare data is vast and fragmented, making it difficult to identify the right patients, predict outcomes, and connect insights across research, care, and access.
OM1’s AI phenotyping solutions—built on the industry’s most expansive commercially available foundation model—reveal hidden patterns in this data, transforming it into clinically meaningful intelligence that drives better discovery, care, and outcomes access.
Find undiagnosed and undertreated patients quantified by likelihood. Leverage phenotyping from education to screening to intervention.
Identify clinically meaningful subpopulations, such as rapid progressors or high-burden patients, to guide research and engagement.
Forecast new conditions, disease progression, adverse events, complications and long-term outcomes to inform or intervene. PhenOM provides a patient specific estimate of the likelihood of an unlimited number of outcomes.
Estimate response, such as disease outcome, persistence, and switching to inform patient or population decision-making.
Define the clinical or business questions that matter most, such as screening patients in clinical settings, identifying hidden subgroups, predicting progression or adverse medical events or estimating treatment response.
PhenOM analyzes patient records to determine relevant patterns that predict likely diagnoses, future medical events and outcomes based on patients with similar phenotypes. Results are grounded in explainable factors.
Performance metrics are rigorously produced to ensure accuracy and reliability.
Access results through multiple delivery mechanisms including API, applications, EHR integration, or delivered reports, enabling immediate impact for a broad range of stakeholders.
patient-years of real-world training data
patents in digital patient phenotyping and subtyping, outcomes measurement, healthcare AI explainability and more
randomized control trials demonstrating clinical impact
predictions available
Across leading institutions and partners, OM1’s patient finding and outcomes prediction solutions are driving measurable improvements in provider education, diagnostic screening, patient outcomes, and care quality.
PhenOM® is being used to enhance diagnosis and treatment for patients with hidradenitis suppurativa (HS).
PhenOM helps identify patients at high risk for undiagnosed Fabry Disease and also predicts likelihood of cardiovascular outcomes.
PhenOM-powered Joint Insights™ improved decision quality and patient experience in a randomized controlled trial (JAMA Network Open, 2021)
Before AI was a buzzword, OM1 built it for healthcare. As the original patent holder for digital patient phenotyping, our PhenOM Foundation Model creates “digital fingerprints” of disease by analyzing patterns across millions of real-world patient journeys. These fingerprints reveal patient subgroups, predict outcomes, and deliver clinically explainable insights trusted by leading life sciences and healthcare partners.

Who We Help
OM1 helps biopharma and life sciences teams generate high-quality real-world evidence with speed and scale. Turn real-world data into evidence that accelerates trials, regulatory submissions, and market adoption.
Who We Help
OM1 empowers health systems, specialty networks, and medical associations to transform data into actionable insights that improve care and efficiency. Automate registry participation and data abstraction, predict patient outcomes at the point of care, and join a research network that advances care.
Who We Help
OM1 enables payers to proactively identify high-risk members, measure the ROI of care management programs, and optimize benefit design using real-world outcomes data and predictive analytics. Our AI models reveal risk trajectories, disease burden, and intervention impact to help payers act earlier and more effectively.
From research and evidence to predictive insights and beyond.